Genomic alterations associated with early stages of breast tumor metastasis

Annals of Surgical Oncology

Volumn 15, Issue 7, 2008, Pages 1989-1995

  Ellsworth, Rachel E ^a,b   Ellsworth, Darrell L ^b   Patney, Heather L ^b   Deyarmin, Brenda ^b   Hooke, Jeffrey A ^c   Love, Brad ^d   Shriver, Craig D ^c   Cronin, Kerri ^c  

^a Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^b WINDBER RESEARCH INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d INVITROGEN CORPORATION   (United States)

Author keywords

Allelic imbalance; Metastasis; Primary breast tumor

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; BREAST TUMOR; CANCER STAGING; CHROMOSOME 8Q; CHROMOSOME MUTATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; REAL TIME POLYMERASE CHAIN REACTION;

ALLELIC IMBALANCE; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENOME; HUMANS; LYMPHATIC METASTASIS; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 46149093205     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9902-5     Document Type: Article

References (39)

1. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89
2. National Cancer Institute. SEER cancer statistics review, 1973-1991. NIH Publ. No. 94-2789. 1994. Bethesda, MD, NIH
3. Ellsworth RE, Ellsworth DL, Neatrour DM, et al. Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 2005;3:71-7
4. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997; 57:1597-604
5. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100:7737-42
6. Newman B, Austin MA, Lee M, et al. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci 1988; 85:3044-8
7. Page DL, Dupont WD, Rogers LW, et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49:751-8
8. Ellsworth DL, Shriver CD, Ellsworth RE, et al. Laser capture microdissection of paraffin-embedded tissues. BioTechniques 2003; 34:42-6
9. Ellsworth RE, Ellsworth DL, Lubert SM, et al. High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:915-9
10. Medintz IL, Lee C-CR, Wong WW, et al. Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 2000; 10:1211-8
11. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 2000; 157:55-81
12. Hartveit E. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology 1990; 16:533-43
13. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438:820-7
14. Hiratsuka S, Watanabe A, Aburatani H, et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8:1369-75
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67
16. Bissig H, Richter J, Desper R, et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol 1999; 155:267-74
17. Sasatomi E, Finkelstein SD, Woods JD, et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 2002; 62:2681-9
18. Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990; 55:87-132
19. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-8
20. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283:139-46
21. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49-54
22. van't Veer LJ, Dai H, vande Vijver MJ, et al. Gene expression profiling predicts clincial outcome of breast cancer. Nature 2002; 415:530-6
23. van de Vijer MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009
24. Weigelt B, Glas AM, Wessels LF, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003; 100:15901-5
25. Sleeman JP, Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis 2007; 24:707-15
26. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-49
27. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115:44-55
28. Kerangueven F, Essioux L, Dib A, et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 1995; 10:1023-6
29. Lichy JH, Dalbegue F, Zavar M, et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 2000; 80:291-301
30. Hermsen MA, Baak JP, Meijer GA, et al. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol 1998; 186:356-62
31. Guerin M, Barrois M, Terrier MJ, et al. Overexpression of either c-myc or c-erB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 1988; 3:21-31
32. Varley JM, Swallow JE, Brammar WJ, et al. Alterations to either c-erbB(neu) or c-myc proto-congoenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987; 1:423-30
33. Machotka SV, Garrett CT, Schwartz AM, et al. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer. Clin Chim Acta 1989; 184:207-17
34. Nagayama K, Watatani M. Analysis of genetic alterations related to the development and progression of breast carcinoma. Jpn J Cancer Res 1993; 84:1159-64
35. Levens D. Disentangling the MYC web. Proc Natl Acad Sci USA 2002; 99:5757-9
36. Brouillet JP, Theillet C, Maudelonde T, et al. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 1990; 26:437-41
37. Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16:483-96
38. Kaplan RN, Rafii S, Lyden D. Preparing the "Soil": the premetastatic niche. Cancer Res 2006; 66:11089-93
39. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002; 16:2530-43